Does Letrozole Cause Bloating?
Abdominal bloating is not a commonly reported side effect of letrozole in breast cancer treatment, and it does not appear in the FDA-approved drug label as a recognized adverse reaction.
Evidence from FDA Drug Label
The FDA label for letrozole 1 provides comprehensive adverse reaction data from controlled clinical trials. Bloating is notably absent from the list of adverse reactions occurring in ≥5% of patients. The gastrointestinal side effects that were documented include:
- Nausea (13-15%)
- Constipation (6-7%)
- Diarrhea (5-6%)
- Abdominal pain (6-9%)
- Vomiting (7%)
- Dyspepsia (3-4%)
The FDA label specifically mentions "abdominal pain" but does not list "bloating" or "abdominal distension" as recognized adverse reactions, even among the less frequent (<5%) consequential adverse reactions.
Clinical Context from Guidelines
The NCCN and Journal of Clinical Oncology guidelines 2, 3 extensively discuss letrozole's side effect profile in breast cancer survivorship. These guidelines emphasize:
- Musculoskeletal pain (most common complaint)
- Bone loss and fractures
- Cardiovascular effects (hypertension, lipid changes)
- Hot flashes
- Fatigue
Bloating is not mentioned as a recognized toxicity requiring monitoring or management in breast cancer patients on letrozole.
Alternative Explanation
If a patient on letrozole reports bloating, consider:
- Coincidental gastrointestinal conditions unrelated to letrozole
- Dietary factors or irritable bowel syndrome (one study 4 showed letrozole actually improved abdominal bloating in women with endometriosis)
- Other medications the patient may be taking
- Weight gain (which occurs in 2% of patients per FDA label) may be perceived as bloating
Clinical Recommendation
If a breast cancer patient on letrozole complains of bloating, investigate other causes rather than attributing it to the medication. The symptom warrants standard gastrointestinal evaluation including assessment for:
- Dietary triggers
- Constipation (which IS a known letrozole side effect at 6-7%)
- Concurrent medications
- Underlying GI disorders
- Metabolic issues (given cardiovascular risk factors associated with aromatase inhibitors)
Do not discontinue letrozole based on bloating alone, as this symptom lacks established causality with the medication and letrozole provides significant mortality benefit in hormone receptor-positive breast cancer 2.